Importantly, pharmacological inhibitors of TPC2 are potentially beneficial for the treatment of Ebola virus, SARS-CoV-2, Parkinson’s disease, and Alzheimer’s disease [35, 40, 41, 43], highlighting that TPC2 may be a suitable drug target for a plethora of pathophysiological processes. Here, TPCN2 is linked to early-onset autosomal dominant Alzheimer disease.